FDA Grants Lete-cel BTD in Myxoid/Round Cell Liposarcoma
The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.
Related Articles
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
Hema Now: Episode 8: What’s Next in Lymphoma Diagnosis and Treatment?
Uncover the future of lymphoma care with Marc Hoffman, Professor, Hematologic Malignancies at the University of Kansas Medical Center.
OncLive’s December Roundup of Key FDA Approvals in Oncology
Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada
Obesity at cancer diagnosis was independently associated with inferior outcome in children and adolescents with cancer, particularly in patients with acute lymphoblastic leukemia and central…
Working on the Frontlines of a Revolution in Multiple Myeloma Care
A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly…
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Nature Medicine – In the TRACERx cohort of 171 patients with lung cancer, the ultrasensitive detection of ctDNA improves preoperative patient stratification, also in early-stage…